Can probiotics play a role in Helicobacter pylori (H. Pylori) eradication?

IF 0.8 Q4 GASTROENTEROLOGY & HEPATOLOGY Egyptian Liver Journal Pub Date : 2023-11-18 DOI:10.1186/s43066-023-00294-4
Sameh Mohamed Fakhry, Mohamed Abdel-Hameed Kandyl, Adel Ferig Hashish, Wafaa Kandeel, Ahmed Mostafa El-Shenawy, Hoda Samir El-Sayed, Mohamed Kamal Dewidar, Sameh Mohamed Badr, Nayra Shaker Mehanna
{"title":"Can probiotics play a role in Helicobacter pylori (H. Pylori) eradication?","authors":"Sameh Mohamed Fakhry, Mohamed Abdel-Hameed Kandyl, Adel Ferig Hashish, Wafaa Kandeel, Ahmed Mostafa El-Shenawy, Hoda Samir El-Sayed, Mohamed Kamal Dewidar, Sameh Mohamed Badr, Nayra Shaker Mehanna","doi":"10.1186/s43066-023-00294-4","DOIUrl":null,"url":null,"abstract":"H. Pylori is one of the commonest infectious diseases worldwide. In recent years, PPI-based triple therapy has been described to be losing its efficacy against H. pylori due to high rates of antibiotic resistance, antibiotics-associated side effects, and low compliance. Probiotics are suggested to improve the H. pylori eradication rate when added to H pylori therapy. Probiotics have anti-inflammatory and anti-oxidative mechanisms that may improve bowel microecology and interact with the microbial flora of the gastrointestinal tract to produce a beneficial effect in H Pylori eradication. Probiotics may be also responsible for the reduction of the adverse effects related to H. pylori therapy that may result in treatment failure. In our study, we assessed the role of probiotics in improving the H. Pylori eradication rate and reducing side effects after antibiotic-based therapy. One hundred fifty-nine patients positive for H. pylori stool antigen and had never received previously H. pylori eradication therapy, were included in the study, 59 patients received triple therapy alone (Standard group) and 100 patients received triple therapy and probiotics (study group). One hundred fifty patients completed the treatment. Quantification of Lactobacilli and Bifidobacteria concentration in stool was done by PCR before and after therapy. Eradication of H. pylori was assessed in each group by H. pylori stool antigen after 4 weeks of finishing therapy. H Pylori eradication rate was higher in patients who received probiotics with standard therapy compared to those who received standard therapy alone. The improvement in the eradication rate was statistically significant when probiotics were received after standard therapy (81.04% versus 71.19%, P-Value 0.021). Short-term diarrhea after antibiotics therapy was significantly lower in patients who received probiotics especially when given before antibiotic therapy (7.50% versus 25.50%, P-value 0.0001). Probiotics may play a role to restore gut dysbiosis as evidenced by stool PCR for Lactobacilli and Bifidobacteria before and after therapy. Probiotics have a beneficial role to improve the eradication rate of H. pylori, particularly when given after standard therapy. Adding probiotics was associated as well with less diarrhea as a side effect of antibiotic therapy. The trial has been registered on the Pan African Clinical Trial Register website, No of registration, PACTR202304859303467. Registered 24 April 2023 - Retrospectively registered, https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=25434 .","PeriodicalId":11620,"journal":{"name":"Egyptian Liver Journal","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Liver Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43066-023-00294-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

H. Pylori is one of the commonest infectious diseases worldwide. In recent years, PPI-based triple therapy has been described to be losing its efficacy against H. pylori due to high rates of antibiotic resistance, antibiotics-associated side effects, and low compliance. Probiotics are suggested to improve the H. pylori eradication rate when added to H pylori therapy. Probiotics have anti-inflammatory and anti-oxidative mechanisms that may improve bowel microecology and interact with the microbial flora of the gastrointestinal tract to produce a beneficial effect in H Pylori eradication. Probiotics may be also responsible for the reduction of the adverse effects related to H. pylori therapy that may result in treatment failure. In our study, we assessed the role of probiotics in improving the H. Pylori eradication rate and reducing side effects after antibiotic-based therapy. One hundred fifty-nine patients positive for H. pylori stool antigen and had never received previously H. pylori eradication therapy, were included in the study, 59 patients received triple therapy alone (Standard group) and 100 patients received triple therapy and probiotics (study group). One hundred fifty patients completed the treatment. Quantification of Lactobacilli and Bifidobacteria concentration in stool was done by PCR before and after therapy. Eradication of H. pylori was assessed in each group by H. pylori stool antigen after 4 weeks of finishing therapy. H Pylori eradication rate was higher in patients who received probiotics with standard therapy compared to those who received standard therapy alone. The improvement in the eradication rate was statistically significant when probiotics were received after standard therapy (81.04% versus 71.19%, P-Value 0.021). Short-term diarrhea after antibiotics therapy was significantly lower in patients who received probiotics especially when given before antibiotic therapy (7.50% versus 25.50%, P-value 0.0001). Probiotics may play a role to restore gut dysbiosis as evidenced by stool PCR for Lactobacilli and Bifidobacteria before and after therapy. Probiotics have a beneficial role to improve the eradication rate of H. pylori, particularly when given after standard therapy. Adding probiotics was associated as well with less diarrhea as a side effect of antibiotic therapy. The trial has been registered on the Pan African Clinical Trial Register website, No of registration, PACTR202304859303467. Registered 24 April 2023 - Retrospectively registered, https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=25434 .
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
益生菌能在根除幽门螺杆菌中发挥作用吗?
幽门螺杆菌是世界上最常见的传染病之一。近年来,基于ppi的三联疗法由于抗生素耐药率高、抗生素相关副作用和低依从性而失去了对幽门螺杆菌的疗效。建议在幽门螺杆菌治疗中添加益生菌,以提高幽门螺杆菌的根除率。益生菌具有抗炎和抗氧化机制,可以改善肠道微生态,并与胃肠道微生物菌群相互作用,产生有益的幽门螺杆菌根除作用。益生菌也可能对减少与幽门螺杆菌治疗相关的可能导致治疗失败的不良反应负责。在我们的研究中,我们评估了益生菌在提高幽门螺杆菌根除率和减少抗生素治疗后副作用方面的作用。159例幽门螺杆菌粪便抗原阳性且从未接受过根除幽门螺杆菌治疗的患者被纳入研究,59例患者单独接受三联治疗(标准组),100例患者接受三联治疗和益生菌治疗(研究组)。150名患者完成了治疗。采用PCR方法检测治疗前后粪便中乳酸杆菌和双歧杆菌的浓度。治疗结束4周后,采用幽门螺杆菌粪便抗原法评估各组幽门螺杆菌根除情况。与单独接受标准治疗的患者相比,接受标准治疗的益生菌患者的幽门螺杆菌根除率更高。标准治疗后给予益生菌对根除率的改善有统计学意义(81.04% vs 71.19%, p值0.021)。抗生素治疗后短期腹泻在服用益生菌的患者中显著降低,尤其是在抗生素治疗前服用益生菌的患者(7.50% vs 25.50%, p值0.0001)。益生菌可能在恢复肠道生态失调中发挥作用,治疗前后的粪便乳酸杆菌和双歧杆菌PCR证实了这一点。益生菌对提高幽门螺杆菌的根除率有有益的作用,特别是在标准治疗后给予。作为抗生素治疗的副作用,添加益生菌也与减少腹泻有关。该试验已在泛非临床试验注册网站注册,注册号为PACTR202304859303467。注册于2023年4月24日-追溯注册,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=25434。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Egyptian Liver Journal
Egyptian Liver Journal Medicine-Hepatology
CiteScore
1.60
自引率
0.00%
发文量
60
审稿时长
9 weeks
期刊最新文献
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals Advancements in ascites management: a comprehensive narrative review of the Alfa Pump system Rifaximin alone vs combination with norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis with hepatic encephalopathy: randomized controlled trial Effect of probiotic, prebiotic, and synbiotic supplementation on circadian clock in rats with fructose-induced non-alcoholic fatty liver Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1